Gwo Xi Stem Cell Applied Technology Co. , Ltd (TPEX:6704)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
22.00
-0.25 (-1.12%)
Mar 24, 2026, 1:57 PM CST
Market Cap2.12B -16.3%
Revenue (ttm)184.91M +22.9%
Net Income-70.14M
EPS-0.73
Shares Out95.95M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume101,113
Average Volume122,465
Open22.25
Previous Close22.25
Day's Range21.70 - 22.50
52-Week Range19.80 - 33.65
Beta0.05
RSI25.48
Earnings DateMar 27, 2026

About TPEX:6704

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the tr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6704
Full Company Profile

Financial Performance

In 2024, TPEX:6704's revenue was 170.03 million, an increase of 20.44% compared to the previous year's 141.18 million. Losses were -83.32 million, -5.41% less than in 2023.

Financial Statements